Personalis, Inc. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
Personalis, Inc. (PSNL) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $93.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-04
- Personalis, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $69.10M, a 73.03% increase year-over-year.
- Personalis, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $24.10M, a 45.54% decline year-over-year.
- Personalis, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $39.42M, a 97.13% increase year-over-year.
- Personalis, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $68.50M, a 522.73% increase year-over-year.
- Personalis, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $192.11M, a 118.31% increase from fiscal 2024.
- Personalis, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $88.00M, a 31.23% decline from fiscal 2023.
- Personalis, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $127.95M, a 42.86% decline from fiscal 2022.
- Personalis, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $223.92M, a 5.09% increase from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $69.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $93.20M 10-Q · filed 2026-08-04 | $132.63M derived: sum of 3 quarters · filed 2026-08-04 | $201.13M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $24.10M 10-Q · filed 2026-05-07 | $63.52M derived: sum of 2 quarters · filed 2026-05-07 | $132.03M derived: sum of 3 quarters · filed 2026-05-07 | $171.96M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $39.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $107.92M derived: sum of 2 quarters · filed 2026-02-26 | $147.86M derived: sum of 3 quarters · filed 2026-08-04 | $192.11M 10-K · filed 2026-02-26 |
| 2025-09-30 | $68.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $108.44M derived: sum of 2 quarters · filed 2026-08-04 | $152.69M 10-Q · filed 2025-11-04 | $172.69M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $39.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $84.19M 10-Q · filed 2026-08-04 | $104.19M derived: sum of 3 quarters · filed 2026-08-04 | $115.19M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $44.25M 10-Q · filed 2026-05-07 | $64.25M derived: sum of 2 quarters · filed 2026-05-07 | $75.25M derived: sum of 3 quarters · filed 2026-05-07 | $96.75M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $31.00M derived: sum of 2 quarters · filed 2026-02-26 | $52.50M derived: sum of 3 quarters · filed 2026-02-26 | $88.00M 10-K · filed 2026-02-26 |
| 2024-09-30 | $11.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $32.50M derived: sum of 2 quarters · filed 2025-11-04 | $68.00M 10-Q · filed 2025-11-04 | $92.00M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $21.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $57.00M 10-Q · filed 2025-08-05 | $81.00M derived: sum of 3 quarters · filed 2025-08-05 | $121.20M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $35.50M 10-Q · filed 2025-05-06 | $59.50M derived: sum of 2 quarters · filed 2025-05-06 | $99.70M derived: sum of 3 quarters · filed 2025-05-06 | $124.36M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $24.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $64.20M derived: sum of 2 quarters · filed 2025-02-27 | $88.86M derived: sum of 3 quarters · filed 2025-02-27 | $127.95M 10-K · filed 2025-02-27 |
| 2023-09-30 | $40.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $64.86M derived: sum of 2 quarters · filed 2024-11-06 | $103.95M 10-Q · filed 2024-11-06 | $145.66M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $24.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $63.76M 10-Q · filed 2024-08-07 | $105.45M derived: sum of 3 quarters · filed 2024-08-07 | $164.27M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $39.10M 10-Q · filed 2024-05-08 | $80.80M derived: sum of 2 quarters · filed 2024-05-08 | $139.62M derived: sum of 3 quarters · filed 2024-05-08 | $197.85M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $41.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $100.52M derived: sum of 2 quarters · filed 2024-02-28 | $158.75M derived: sum of 3 quarters · filed 2024-02-28 | $223.92M 10-K · filed 2024-02-28 |
| 2022-09-30 | $58.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $117.05M derived: sum of 2 quarters · filed 2023-11-07 | $182.22M 10-Q · filed 2023-11-07 | $265.52M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $58.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $123.41M 10-Q · filed 2023-08-08 | $206.71M derived: sum of 3 quarters · filed 2024-02-28 | $259.98M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $65.17M 10-Q · filed 2023-05-03 | $148.47M derived: sum of 2 quarters · filed 2024-02-28 | $201.75M derived: sum of 3 quarters · filed 2024-02-28 | $251.37M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $83.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $136.57M derived: sum of 2 quarters · filed 2024-02-28 | $186.19M derived: sum of 3 quarters · filed 2024-02-28 | $213.08M 10-K · filed 2024-02-28 |
| 2021-09-30 | $53.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $102.89M derived: sum of 2 quarters · filed 2022-11-02 | $129.78M 10-Q · filed 2022-11-02 | $149.15M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $49.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $76.51M 10-Q · filed 2022-08-03 | $95.88M derived: sum of 3 quarters · filed 2023-02-23 | $116.07M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $26.89M 10-Q · filed 2022-05-04 | $46.26M derived: sum of 2 quarters · filed 2023-02-23 | $66.46M derived: sum of 3 quarters · filed 2023-02-23 | $99.49M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $19.37M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $39.56M derived: sum of 2 quarters · filed 2023-02-23 | $72.59M derived: sum of 3 quarters · filed 2023-02-23 | $99.88M 10-K · filed 2023-02-23 |
| 2020-09-30 | $20.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $53.23M derived: sum of 2 quarters · filed 2021-11-04 | $80.51M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $33.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $60.31M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $27.28M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $5.70M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |